U.S. Tobacco Stock News

NasdaqCM:LMB
NasdaqCM:LMBConstruction

Is Limbach Holdings (LMB) Still Attractive After Recent Share Price Pullback?

If you are asking yourself whether Limbach Holdings at around US$81.51 is still good value or starting to look expensive, this review is for you. The stock has moved around recently, with a 7 day return of a 16.8% decline, a 30 day return of a 9.1% decline, a 3.1% gain year to date, and an 11.6% gain over the past year. The 3 year return is very large and the 5 year return is also very large. Recent coverage has focused on Limbach as a specialist player in capital goods and building systems,...
NasdaqGS:TTMI
NasdaqGS:TTMIElectronic

Are Volatility and Insider Sales Obscuring TTM Technologies’ (TTMI) AI-Driven Investment Narrative?

In recent days, TTM Technologies has been swept up in a broader technology sector swing, with AI and semiconductor enthusiasm lifting sentiment while geopolitical tensions and higher oil prices briefly weighed on investor confidence. At the same time, insider share sales under a pre-arranged trading plan and the stock’s frequent large price moves underline how sensitive TTM remains to sector news and macro shocks rather than company-specific shifts. With this backdrop of AI-driven optimism...
NasdaqGS:ALAB
NasdaqGS:ALABSemiconductor

Astera Labs Deepens AI Connectivity With Photonics Push And Israel Expansion

Astera Labs agreed to acquire aiXscale Photonics, adding optical and photonics capabilities to its AI connectivity portfolio. The company is launching an Israel Design Center focused on high speed data and AI infrastructure solutions. Astera Labs is expanding ecosystem partnerships, including its role in the UALink consortium and work with major hyperscalers. Astera Labs (NasdaqGS: ALAB) is leaning further into the AI infrastructure theme with a share price of $120.0 and a value score of 1...
NYSE:APG
NYSE:APGConstruction

APi Group Leans On Inspection First Model To Build Cash And Scale

APi Group (NYSE:APG) reports record revenue levels alongside higher profitability. The company highlights 21 consecutive quarters of double digit inspection growth in North America. Management continues to pursue bolt on acquisitions while expanding free cash flow margins. APi Group, listed on the NYSE under the ticker APG, focuses on safety and specialty services with an inspection first model that aims to drive recurring revenue. Recent updates around record revenue, stronger...
NYSE:D
NYSE:DIntegrated Utilities

A Look At Dominion Energy (D) Valuation As Capex Plan And Earnings Momentum Attract Investor Attention

Dominion Energy (D) just paired a larger capital spending plan of US$64.7b for 2026 to 2030 with full year 2025 earnings that show higher sales and net income, catching investors’ attention. See our latest analysis for Dominion Energy. The stronger earnings update and larger capex plan come after a 7.71% 90 day share price return and 22.77% 1 year total shareholder return. This suggests momentum has been building as investors reassess growth and risk in light of new data center contracts. If...
NasdaqGS:ALNY
NasdaqGS:ALNYBiotechs

Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After Recent Share Price Pullback

Wondering whether Alnylam Pharmaceuticals at around US$320 a share still makes sense for your portfolio, or if the value case has shifted? This article will walk you through what the current price might be implying. The stock has been volatile recently, with a 3.2% decline over the last week, an 8.9% decline over the past month, a 19.9% decline year to date, yet a 29.2% return over 1 year, 72.4% over 3 years, and 124.2% over 5 years. These moves sit against a backdrop of ongoing attention on...
NasdaqGS:DNLI
NasdaqGS:DNLIBiotechs

Denali Therapeutics (DNLI) Is Down 8.0% After Wider Losses And New Shelf Filing Has The Bull Case Changed?

Denali Therapeutics Inc. recently reported fourth-quarter and full-year 2025 results, with net losses of US$128.55 million for the quarter and US$512.54 million for the year, and also filed a US$200.73 million shelf registration for 9,370,929 common shares tied to an ESOP-related offering. Alongside these wider losses and potential equity issuance, Denali is maintaining visibility with investors through a company presentation at TD Cowen’s 46th Annual Health Care Conference held on March 4,...
NasdaqGS:WIX
NasdaqGS:WIXIT

Wix Buyback And AI Shift Raise Questions On Valuation And Risk

Wix.com (NasdaqGS:WIX) has approved a major share repurchase program that includes a large modified Dutch auction tender offer. The company has raised US$250 million through a private placement led by Durable Capital Partners. Wix is accelerating its shift toward AI powered software with the launch of Wix Harmony and the acquisition of Base44. Wix.com, best known for its website building tools, is signaling a new phase as it moves further into broader software applications and AI centric...
NYSE:MOD
NYSE:MODBuilding

Modine Earnings Beat Highlights Data Center Push And Spin Off Plan

Modine Manufacturing (NYSE:MOD) reported Q3 FY2026 results that were ahead of its own expectations. The company raised its full year FY2026 guidance following the quarter. Management highlighted strong growth in Modine's data center related business. Modine announced plans to spin off its Performance Technologies segment into a separate company. Modine Manufacturing focuses on thermal management and engineered solutions across transportation, industrial, and building markets, with data...
NasdaqGS:CAR
NasdaqGS:CARTransportation

Avis Smoke Free Fleet Policy And What It Could Mean For CAR Stock

Avis Budget Group (NasdaqGS:CAR) has imposed a company wide ban on smoking in all North American rental vehicles. The new policy introduces significant penalties for customers who violate the smoke free rules. Avis is the first major rental car company to roll out a blanket smoke free fleet policy at this scale. Health advocacy groups are publicly supporting the move, highlighting its focus on cleaner and healthier vehicles. Avis Budget Group, the parent of Avis and Budget, operates a large...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Incyte’s Cash Flow Gains Reshape Earnings Outlook And Capital Return Options

Incyte, ticker NasdaqGS:INCY, is reporting sustained revenue growth alongside an expansion in free cash flow margins. The company is also showing strong earnings momentum, pointing to robust operational performance. These trends highlight an improved ability to invest in the business or return value to shareholders through capital allocation choices. For investors tracking NasdaqGS:INCY, the latest numbers focus attention on how the business is running, not just where the share price sits...
NasdaqGS:AMLX
NasdaqGS:AMLXPharmaceuticals

Amylyx Pharmaceuticals (AMLX) Valuation Check After Improved Results And LUCIDITY Trial Enrollment Completion

Amylyx Pharmaceuticals (AMLX) drew fresh attention after reporting fourth quarter and full year 2025 results that showed smaller losses, while also completing enrollment in its pivotal Phase 3 LUCIDITY trial for avexitide. See our latest analysis for Amylyx Pharmaceuticals. Despite the earnings beat and progress in its pipeline, Amylyx Pharmaceuticals’ recent share price performance has cooled a little, with a 1-day share price return of 6.31% decline and a 7-day share price return of 7.6%...
NasdaqGS:HUBG
NasdaqGS:HUBGLogistics

Hub Group (HUBG) Valuation After $77 Million Accounting Error And Delayed Annual Report

Hub Group (HUBG) has been under pressure after disclosing a $77 million accounting error tied to understated transportation costs and accounts payable. This issue forced delayed 2025 reporting and triggered external investigations into its financial controls. See our latest analysis for Hub Group. The stock has been under pressure recently, with a 1 month share price return of 18.26% decline and a 7 day share price return of 3.95% decline, as investors react to the accounting error, delayed...
NYSE:ASGN
NYSE:ASGNIT

Assessing ASGN (ASGN) Valuation After Recent Share Price Volatility

ASGN (ASGN) has drawn investor attention after recent share price moves, with the stock up 2.8% over the past day but showing weaker performance over the past month and the past 3 months. See our latest analysis for ASGN. That 2.8% 1 day share price gain comes after a tougher stretch, with a 30 day share price return of 15.1% decline and a 1 year total shareholder return of 37% decline. This suggests recent momentum has been fading as investors reassess growth expectations and risk. If ASGN’s...
NYSE:BR
NYSE:BRProfessional Services

Is Broadridge Financial Solutions (BR) Offering Value After Recent Share Price Weakness

If you are wondering whether Broadridge Financial Solutions is reasonably priced or offering value right now, you will want to see how its current share price stacks up against a few different valuation yardsticks. The stock last closed at US$190.89, with returns of 4.2% over the past week and 2.7% over the past month, set against a year to date return of 13.4% decline and a 1 year return of 18.5% decline, while the 3 year and 5 year returns sit at 42.2% and 43.6% respectively. Recent news...
NYSE:WES
NYSE:WESOil and Gas

Is Western Midstream Partners (WES) Pricing Reflect Its Cash Flow And P/E Signals After Recent Gains

If you are looking at Western Midstream Partners and wondering whether the current price reflects its true worth, this article will walk you through the key signals that matter. The units last closed at US$42.19, with returns of 2.5% over the past week, 4.7% over the past month, 6.2% year to date and 22.3% over the last year, plus very large gains over 3 and 5 years that may have changed how investors view its risk and reward profile. Recent news coverage has focused on Western Midstream...
NasdaqGS:ZBRA
NasdaqGS:ZBRAElectronic

Zebra’s New Healthcare Tools And Valuation Gap Set Stage For HIMSS26

Zebra Technologies, NasdaqGS:ZBRA, has introduced its Orchestrated Care framework for healthcare. The company has also launched the DS82-HC Series scanner, focused on clinician workflows and patient safety. Both offerings are scheduled to be showcased at the HIMSS26 conference. Zebra Technologies is expanding its healthcare solutions with Orchestrated Care and the DS82-HC Series, integrating its hardware and software more closely with clinical workflows. The shares last closed at $229.67,...
NasdaqGS:AXON
NasdaqGS:AXONAerospace & Defense

How Axon’s AI-Driven Q4 Results and 2026 Outlook Could Reshape Axon Enterprise (AXON) Investors

In late February 2026, Axon Enterprise, Inc. reported fourth-quarter 2025 results showing revenue rising to US$796.72 million from US$575.15 million a year earlier, while net income declined to US$2.75 million from US$135.18 million, and issued full-year 2026 guidance calling for 27% to 30% year-over-year revenue growth. The results underscored Axon’s shift toward an AI- and software-centric public safety platform, with products like its Draft One report-writing tool and recent acquisitions...
NYSE:MPLX
NYSE:MPLXOil and Gas

A Look At MPLX (MPLX) Valuation After Recent Multi Period Return Performance

MPLX (MPLX) has drawn attention after recent trading left the unit price near $58.66, with the partnership noting multi year total returns and operating a broad midstream footprint across U.S. pipelines, storage, and logistics. See our latest analysis for MPLX. At a share price of US$58.66, MPLX has seen a 6.13% 1 month share price return and 8.89% year to date share price return, while its 1 year total shareholder return of 21.30% and 5 year total shareholder return of 249.01% point to...
NYSE:BTU
NYSE:BTUOil and Gas

Is It Too Late To Consider Peabody Energy (BTU) After Its 8x Five-Year Run?

Wondering if Peabody Energy at around US$33.28 is still offering value or if most of the easy gains are behind it? This article walks through what the current price might be implying. The stock has had a mixed short term run, with a 3.1% gain over the last week, a 5.5% decline over the last month, an 8.5% return year to date, and a very large return over the past 5 years that is close to 8x. These moves sit against a backdrop of ongoing attention on coal producers, as investors weigh the...
NYSE:AGX
NYSE:AGXConstruction

Assessing Argan (AGX) Valuation After A Short Term Share Price Pullback

What Argan’s recent share move means for investors Argan (AGX) shares closed at $430.25 after a mixed recent run, with a 7.1% decline over the past day and a 4.9% drop over the past week, despite longer term gains. For investors, that combination of short term weakness and stronger month and past 3 months performance raises a practical question: how does the current price line up with Argan’s fundamentals and recent business trends? See our latest analysis for Argan. Set against a strong...
NYSE:NOMD
NYSE:NOMDFood

Is Nomad Foods (NOMD) Starting To Look Interesting After A 47% One Year Share Price Slide

If you are wondering whether Nomad Foods at US$10.33 is starting to look like value or a value trap, you are not alone. That is exactly what this article will unpack. The stock has seen an 8.3% decline over the last week, an 18.0% drop over the past month, and is down 47.0% over the past year, putting long term holders under pressure and raising fresh questions about risk and return. Recent coverage has focused on how prolonged share price weakness and earlier acquisition activity have...
NYSE:MLM
NYSE:MLMBasic Materials

Martin Marietta (MLM) Lifts 2026 Volume Outlook After Q4 Miss and Acquisitions Integration Update

In February 2026, Martin Marietta Materials updated its 2026 earnings guidance, targeting midpoint revenues of US$7,160 million and 12% volume growth, incorporating expected contributions from the QUIKRETE transaction and Minnesota aggregates and FOB asphalt assets acquired from CRH in late 2025. This guidance update arrives soon after a disappointing Q4 2025 earnings miss and new acquisitions such as Premier Magnesia, highlighting a contrast between recent operational setbacks and...
NYSE:RVTY
NYSE:RVTYLife Sciences

The Bull Case For Revvity (RVTY) Could Change Following Cautious 2026 Outlook And Capital Allocation Scrutiny

Revvity recently reported past fourth-quarter 2025 results with adjusted earnings of US$1.70 per share on 5.9% revenue growth, while issuing 2026 guidance that aligned with but did not lift already reduced analyst expectations. A contemporaneous Bretton Fund letter criticized Revvity’s use of its Covid testing windfall on overpriced deals and divestitures, highlighting investor unease with management’s capital allocation choices despite the company’s remaining potential. We’ll now examine...